Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 10, 1998, Pages 1255-1260

  Dubé, Daniel ^a   Blouin, Marc ^a   Brideau, Christine ^a   Chan, Chi Chung ^a   Desmarais, Sylvie ^a   Ethier, Diane ^a   Falgueyret, Jean Pierre ^a   Friesen, Richard W ^a   Girard, Mario ^a   Girard, Yves ^a   Guay, Jocelyne ^a   Riendeau, Denis ^a   Tagari, Philip ^a   Young, Robert N ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 7 [3 FLUORO 5 (3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCT 3 YL)PHENOXYMETHYL] 4 (3 FURYL)QUINOLINE; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; ARACHIDONATE 5 LIPOXYGENASE; ISOQUINOLINE DERIVATIVE; LIPOXYGENASE INHIBITOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ASTHMA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; INFLAMMATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ARACHIDONATE 5-LIPOXYGENASE; BICYCLO COMPOUNDS; HUMANS; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NAPHTHALENES; NEUTROPHILS; QUINOLINES; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 17544392459     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00201-7     Document Type: Article

References (23)

1. 1. Brooks, C. D. W.; Summers, J. B. J. Med. Chem. 1996, 39, 2629.
2. 2. 5-LO or FLAP inhibitors, recent clinical results: (a) Israel, E.; Rubin, P.; Kemp, J. P.; Grossman, J.; Pierson, W.; Siegel, S. C.; Tinkelman, D.; Murray, J. J.; Busse, W.; Segal, A. T.; Fish, J.; Kaiser, H. B.; Ledford, D.; Wenzel, S.; Rosenthal, R.; Cohn, J.; Lanni, C.; Perlman, H.; Karahalios, P.; Drasen, J. M. Ann. Intern. Med. 1993, 119, 1059.
3. (b) Friedman, B. S.; Bel, E. H.; Buntinx, A.; Tanaka, W.; Han, Y. H.; Shingo, S.; Spector, R.; Sterk, P. Am. Rev. Respir. Dis. 1993, 147, 839.
4. (c) Diamant, Z.; Timmers, M. C.; Van der Veen, H.; Friedman, B. S; De Smet, M.; Depré, M.; Hilliard, D.; Bel, E.; Sterk, P. J. J. Allergy Clin. Immunol. 1995, 95, 42.
5. 3. Hutchinson, J. H.; Riendeau, D.; Brideau, C.; Chan, C-C; Delorme, D.; Denis, D.; Falgueyret, J.-P.; Fortin, R.; Guay, J.; Hamel, P.; Jones, T. R.; Macdonald, D.; McFarlane, C. S.; Piechuta, H.; Scheigetz, J.; Tagari, P.; Therien, M.; Girard, Y. J. Med. Chem. 1993, 36, 2771.
6. 4. Ducharme, Y.; Brideau, C.; Dubé, D.; Chan, C-C; Falgueyret, J.-P.; Gillard, J. W.; Guay, J.; Hutchinson, J. H.; McFarlane, C. S.; Riendeau, D.; Scheigetz, J.; Girard, Y. J. Med. Chem. 1994, 37, 512.
7. 5. Chauret, N.; Li, C.; Ducharme, Y.; Trimble, L. A.; Yergey, J. A.; Ramachandran, C.; Nicoll-Griffith, D. A. Drug. Metab. Dispos. 1995, 23, 65.
8. 6. Delorme, D.; Ducharme, Y.; Brideau, C.; Chan, C.-C.; Chauret, N.; Desmarais, S.; Dubé, D.; Falgueyret, J.-P.; Fortin, R.; Guay, J.; Hamel, P.; Jones, T. R.; Lépine, C.; Li. C.; McAuliffe, M.; McFarlane, C. S.; Nicoll-Griffith, D. A.; Riendeau, D.; Yergey, J. A.; Girard, Y. J. Med. Chem. 1996, 39, 3951.
9. 7. Hamel, P.; Riendeau, D.; Brideau, C.; Chan, C.-C.; Desmarais, S.; Delorme, D.; Dubé, D.; Ducharme, Y.; Ethier, D.; Grimm, E.; Falgueyret, J.-P.; Guay, J.; Jones, T. R.; Kwong, E.; McAuliffe, M.; McFarlane, C. S.; Piechuta, H.; Roumi, M.; Tagari, P.; Young, R. N.; Girard, Y. J. Med. Chem. 1997, 40, 2866.
10. 8. Rowland, M.; Tozer, T. N. Clinical Pharmacokinetics Concepts and Applications. Lea and Febiger: Philadelphia, 1980; Chapter 3.
11. 9. Falgueyret, J.-P.; Denis, D.; Macdonald, D.; Hutchinson, J. H.; Riendeau, D. Biochemistry 1995, 34, 13603.
12. 10. Brideau, C.; Chan, C.; Charleson, S.; Denis, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Fortin, R.; Gillard, J. W.; Guay, D.; Guévremont, D.; Hutchinson, J. H.; Jones, T. R.; Léger, S.; Mancini, J. A.; McFarlane, C. S.; Pickett, C.; Piechuta, H.; Prasit, P.; Riendeau, D.; Rouzer, C. A.; Tagari, P.; Vickers, P. J.; Young, R. N.; Abraham, W. M. Can. J. Physiol. Pharmacol. 1992, 70, 799.
13. 11. Tagari, P.; Becker, A.; Brideau, C.; Frenette, R.; Sadl, V.; Thomas, E.; Vickers, P.; Ford-Hutchinson, A. J. Pharmacol. Exper. Ther. 1993, 265, 416.
14. 12. Tamao, K.; Sumitani, K.; Kiso, Y.; Zembayashi, M; Fujioka, A.; Kodama, S.-I.; Nakajima, I.; Minato, A.; Kumada, M. Bull. Chem. Soc. Jpn. 1976, 49, 1958.
15. 13. Fife, W. K. J. Org. Chem. 1983, 48, 1375.
16. 14. For example; Szczepankiewics, B. C.; Heathcock, C. H. J. Org. Chem. 1994, 59, 3512. Jones, G. In The Chemistry of Heterocyclic Compounds; Jones, G., Ed.; Wiley: New York, 1977; Vol. 32, pp 151-158.
17. 14. For example; Szczepankiewics, B. C.; Heathcock, C. H. J. Org. Chem. 1994, 59, 3512. Jones, G. In The Chemistry of Heterocyclic Compounds; Jones, G., Ed.; Wiley: New York, 1977; Vol. 32, pp 151-158.
18. 15. Boger, D. L.; Brotherton, C. E.; Kelley, M. D. Tetrahedron 1981, 37, 3977 and references cited therein.
19. 2, HCl (82%).
20. 17. Popp, F. D.; Duarte, F. F. In The Chemistry of Heterocyclic Compounds, Isoquinolines part two; Kathawala, F. G.; Coppola, G. M.; Schuster, H. F., Eds.; Wiley: New York, 1990; p 212.
21. 18. Friesen, R.; Young, R. B.; Girard, Y.; Blouin, M.; Dubé, D. U.S. Patent 5 410 054, 1995.
22. 19. Friesen, R.; Girard, Y.; Dubé, D. U.S. Patent 5 459 271, 1995.
23. 20. Microsomal metabolism studies on L-739,010 and L-746,530 have revealed the formation of reactive intermediates at the dioxabicyclooctanyl. Chauret, N.; Nicoll-Griffith, D.; Friesen, R.; Li, C.; Trimble, L.; Dubé, D.; Fortin, R.; Girard, Y.; Yergey, J. Drug. Metab. Dispos. 1995, 23, 1325.